BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

...remyelination. At least two companies are developing preclinical estrogen receptor agonists for MS: Swedish biotech Karo Pharma AB...
...the dual ESR1 and ESR2 agonist KB9520, and Wisconsin-based Endece LLC has ESR2 agonist NDC-1308. Karo...
...LLC, Mequon, Wis. Harvard Medical School, Boston, Mass. Intellia Therapeutics Inc. (NASDAQ:NTLA), Cambridge, Mass. Karo Pharma AB (SSE:KARO...
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology

...Phase I/II testing to treat Alzheimer’s disease and Phase II testing to treat menopausal symptoms. Karo Pharma AB...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...Therapeutics Inc. has ON 013100, a small molecule eIF4E inhibitor, in preclinical testing for cancer. Karo Pharma AB...
BioCentury | Jan 6, 2017
Product R&D

Viral ambitions

...trial in pregnant mothers is ongoing. For HRV, only two companies, Aviragen Therapeutics Inc. and Karo Pharma AB...
...Atlanta, Ga. Imperial College London, London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Karo Pharma AB (SSE:KARO...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

...Preclinical NDC-1022 ESR2 ESR2 agonist Endece Small molecule Preclinical KB9520 ESR2 Selective ESR2 agonist Karo Pharma AB (SSE:KARO...
BioCentury | Feb 15, 2016
Financial News

Karo Bio proposes rights offering

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date announced: 2016-02-12 Type: Rights offering To be...
BioCentury | Jun 8, 2015
Company News

Tanomed, Karo Bio deal

...Karo acquired Tanomed for 13.5 million new Karo shares at SEK1.48 per share, or SEK20 million...
...SEK1.48 per share, or SEK20 million ($2.3 million). The price is a 1% premium on Karo’s...
...further details, and Tanomed could not be reached. Tanomed AB , Umea, Sweden Karo Bio AB (SSE:KARO...
BioCentury | May 4, 2015
Financial News

Karo Bio proposes rights offering

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date announced: 2015-04-29 Type: Rights offering To be...
BioCentury | May 5, 2014
Financial News

Karo Bio completes rights offering

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date completed: 4/30/14 Type: Rights offering Raised: SEK77.7...
BioCentury | May 5, 2014
Financial News

Karo Bio completes private placement

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date completed: 4/30/14 Type: Private placement Raised: SEK7.1...
Items per page:
1 - 10 of 251
BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

...remyelination. At least two companies are developing preclinical estrogen receptor agonists for MS: Swedish biotech Karo Pharma AB...
...the dual ESR1 and ESR2 agonist KB9520, and Wisconsin-based Endece LLC has ESR2 agonist NDC-1308. Karo...
...LLC, Mequon, Wis. Harvard Medical School, Boston, Mass. Intellia Therapeutics Inc. (NASDAQ:NTLA), Cambridge, Mass. Karo Pharma AB (SSE:KARO...
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology

...Phase I/II testing to treat Alzheimer’s disease and Phase II testing to treat menopausal symptoms. Karo Pharma AB...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...Therapeutics Inc. has ON 013100, a small molecule eIF4E inhibitor, in preclinical testing for cancer. Karo Pharma AB...
BioCentury | Jan 6, 2017
Product R&D

Viral ambitions

...trial in pregnant mothers is ongoing. For HRV, only two companies, Aviragen Therapeutics Inc. and Karo Pharma AB...
...Atlanta, Ga. Imperial College London, London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Karo Pharma AB (SSE:KARO...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

...Preclinical NDC-1022 ESR2 ESR2 agonist Endece Small molecule Preclinical KB9520 ESR2 Selective ESR2 agonist Karo Pharma AB (SSE:KARO...
BioCentury | Feb 15, 2016
Financial News

Karo Bio proposes rights offering

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date announced: 2016-02-12 Type: Rights offering To be...
BioCentury | Jun 8, 2015
Company News

Tanomed, Karo Bio deal

...Karo acquired Tanomed for 13.5 million new Karo shares at SEK1.48 per share, or SEK20 million...
...SEK1.48 per share, or SEK20 million ($2.3 million). The price is a 1% premium on Karo’s...
...further details, and Tanomed could not be reached. Tanomed AB , Umea, Sweden Karo Bio AB (SSE:KARO...
BioCentury | May 4, 2015
Financial News

Karo Bio proposes rights offering

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date announced: 2015-04-29 Type: Rights offering To be...
BioCentury | May 5, 2014
Financial News

Karo Bio completes rights offering

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date completed: 4/30/14 Type: Rights offering Raised: SEK77.7...
BioCentury | May 5, 2014
Financial News

Karo Bio completes private placement

...Karo Bio AB (SSE:KARO), Stockholm, Sweden Business: Endocrine/Metabolic Date completed: 4/30/14 Type: Private placement Raised: SEK7.1...
Items per page:
1 - 10 of 251